Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

IRAK4 inhibition
March 2020
SHARING OPTIONS:

CAMBRIDGE, Mass.—Kymera Therapeutics Inc. recently presented preclinical data on its IRAK4 degraders at the 9th European Hidradenitis Suppurativa Foundation Scientific Conference in Athens. The degraders were found to completely suppress IRAK4 protein expression in skin and immune cells, and also inhibited cutaneous inflammation. The company’s IRAK4 degrader reduced IRAK4 levels in the skin and spleen, and also reduced circulating Th1 and Th17 cytokines (including IL-1b, IL-6 and IL-17) to the same degree as topical corticosteroids. Daily oral dosing for two weeks in higher species resulted in complete suppression of IRAK4 in skin, lymph nodes and peripheral blood mononuclear cells, and was safe and well tolerated. Aberrant activation of TLR and IL-1R signaling pathways is a root cause of inflammatory/immune conditions such as hidradenitis suppurativa, atopic dermatitis and rheumatoid arthritis.

Back



PAGE UTILITIES


CONTACT US
DDNEWS
478 Bay Street, Suite A213
Midland, Ontario, Canada L4R 1K9
Ph: 888-781-0328 |  Fax: 705-528-0270
 
© Copyright 2020 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.